 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | IMM01 / ImmuneOnco Biopharma, losartan/aldesleukin (IMM-01) / Modulate Therap
Journal: DAAM2 Variants Cause Nephrotic Syndrome via Actin Dysregulation. (Pubmed Central) - Jan 13, 2021
We conclude that DAAM2 variants are a likely cause of monogenic human SRNS due to actin dysregulation in podocytes. Further, we provide evidence that DAAM2-associated SRNS may be amenable to treatment using actin regulating compounds.
- | losartan/aldesleukin (IMM-01) / Modulate Therap
New P1 trial, Monotherapy, Checkpoint inhibition, Metastases: Study to Evaluate the Safety of IMM-01 in Patients With Advanced Solid Tumours (clinicaltrials.gov) - Sep 10, 2020
P1, N=10, Not yet recruiting, Sponsor: Modulate Therapeutics Ltd
- IMM01 / ImmuneOnco Biopharma, IMM-01 / Modulate Therap
Mutations in the Diaphanous Related Formin DAAM2 as a Novel Cause of Nephrotic Syndrome (Exhibit Hall, Walter E. Washington Convention Center) - Oct 14, 2019 - Abstract #KIDNEYWEEK2019KIDNEY_WEEK_2925;
DAAM2 is likely a potential target for formin activating drugs. Funding NIDDK Support